Parallel Advisors’s Solid Biosciences SLDB Stock Holding History

Parallel Advisors’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.25K	Hold	125	–	–	﹤0.01%	3641
2026 Q1	$900	Hold	125	–	–	﹤0.01%	3559
2025 Q4	$705	Hold	125	–	–	﹤0.01%	3359
2025 Q3	$771	Hold	125	–	–	﹤0.01%	3274
2025 Q2	$609	Buy	125 +118	+1,686%	+$417	﹤0.01%	3284
2025 Q1	$26	Hold	7	–	–	﹤0.01%	3482
2024 Q4	$28	Hold	7	–	–	﹤0.01%	3494
2024 Q3	$49	Hold	7	–	–	﹤0.01%	3359
2024 Q2	$40	Buy	7 +1	+17%	+$9	﹤0.01%	3276
2024 Q1	$80	Hold	6	–	–	﹤0.01%	3217
2023 Q4	$37	Hold	6	–	–	﹤0.01%	3264
2023 Q3	$15	Hold	6	–	–	﹤0.01%	3331
2023 Q2	$31	Hold	6	–	–	﹤0.01%	3325
2023 Q1	$28	Hold	6	–	–	﹤0.01%	3381
2022 Q4	$32	Sell	6 -1	-14%	-$7	﹤0.01%	3303
2022 Q3	$0	Hold	7	–	–	﹤0.01%	3465
2022 Q2	$0	Hold	7	–	–	﹤0.01%	3329
2022 Q1	$0	Buy	+7	New	+$124	﹤0.01%	3248
2021 Q4	–	Sell	-19	Closed	-$1K	–	3274
2021 Q3	$1K	Buy	+19	New	+$807	﹤0.01%	2951

Other funds holding SLDB

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors's SLDB Position: Q2 2026 in Review

Parallel Advisors held its Solid Biosciences (SLDB) position steady in Q2 2026 at 125 shares worth $1.25K. The position accounts for ﹤0.01% of the portfolio, ranked #3641.

Parallel Advisors first reported a position in SLDB in Q3 2021 and has held it in 19 quarters since. 157 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

Parallel Advisors held 125 shares of Solid Biosciences worth $1.25K as of Q2 2026.
Parallel Advisors left its Solid Biosciences share count unchanged in Q2 2026.
Solid Biosciences made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3641 holding.
Parallel Advisors first reported a position in Solid Biosciences in Q3 2021 and has held it in 19 quarters since.
157 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.